A Multicenter, Open-Label Study of an Intravenous Short-Acting β1-Adrenergic Receptor Antagonist Landiolol Hydrochloride for Coronary Computed Tomography Angiography by 16-Slice Multi-Detector Computed Tomography in Japanese Patients with Suspected Ischemic Cardiac Disease

Masaharu Hirano; Akira Yamashina; Kazuhiro Hara; Yuji Ikari; Masahiro Jinzaki; Misako Iino; Takuhiro Yamaguchi; Mitsunobu Tanimoto; Sachio Kuribayashi

doi:10.1007/s40268-014-0056-6

A Multicenter, Open-Label Study of an Intravenous Short-Acting β₁-Adrenergic Receptor Antagonist Landiolol Hydrochloride for Coronary Computed Tomography Angiography by 16-Slice Multi-Detector Computed Tomography in Japanese Patients with Suspected Ischemic Cardiac Disease

Masaharu Hirano, Akira Yamashina, Kazuhiro Hara, Yuji Ikari, Masahiro Jinzaki, Misako Iino, Takuhiro Yamaguchi, Mitsunobu Tanimoto, Sachio Kuribayashi

Department of Radiology (Diagnostic Radiology)

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Abstract

Conclusions: Landiolol hydrochloride was confirmed to reduce heart rate significantly and rapidly after intravenous injection and this suggests that the study drug is a safe and useful agent for improving the image quality of CCTA by 16-slice MDCT.

Background: During coronary computed tomography (CT) angiography (CCTA), β-blockers (β-adrenergic receptor antagonists) have commonly been used to lower heart rate and improve image quality.

Results: The diagnosable proportions for the reconstruction images at mid-diastole were 56.0 %. The diagnosable proportions for the optimal reconstruction images were 65.4 %. The mean heart rate-lowering effect was observed soon after administration of landiolol hydrochloride; the peak of the effect was reached in 3–5 min, and the effect wore off in 30 min after completion of administration. The mean heart rate-lowering proportion at that time was −14.46 ± 8.4 %.

Objectives: The aim of this study was to investigate the image quality-improving effect as well as the heart rate-lowering effect of landiolol hydrochloride (an intravenous short-acting β₁-adrenergic receptor antagonist) in CCTA by 16-slice multi-detector CT (MDCT).

Methods: A total of 39 subjects suspected of having ischemic cardiac disease and requiring CCTA received 0.125 mg/kg of landiolol hydrochloride to study the efficacy and safety of landiolol hydrochloride in a multicenter open-label clinical study. The endpoint was the diagnosable proportion (proportion of subjects whose coronary stenosis was diagnosable).

Original language	English
Pages (from-to)	185-194
Number of pages	10
Journal	Drugs in R and D
Volume	14
Issue number	3
DOIs	https://doi.org/10.1007/s40268-014-0056-6
Publication status	Published - 2014 Sept 1

ASJC Scopus subject areas

Pharmacology

Access to Document

10.1007/s40268-014-0056-6

Fingerprint

Dive into the research topics of 'A Multicenter, Open-Label Study of an Intravenous Short-Acting β₁-Adrenergic Receptor Antagonist Landiolol Hydrochloride for Coronary Computed Tomography Angiography by 16-Slice Multi-Detector Computed Tomography in Japanese Patients with Suspected Ischemic Cardiac Disease'. Together they form a unique fingerprint.

Cite this

Hirano, M., Yamashina, A., Hara, K., Ikari, Y., Jinzaki, M., Iino, M., Yamaguchi, T., Tanimoto, M., & Kuribayashi, S. (2014). A Multicenter, Open-Label Study of an Intravenous Short-Acting β₁-Adrenergic Receptor Antagonist Landiolol Hydrochloride for Coronary Computed Tomography Angiography by 16-Slice Multi-Detector Computed Tomography in Japanese Patients with Suspected Ischemic Cardiac Disease. Drugs in R and D, 14(3), 185-194. https://doi.org/10.1007/s40268-014-0056-6

A Multicenter, Open-Label Study of an Intravenous Short-Acting β₁-Adrenergic Receptor Antagonist Landiolol Hydrochloride for Coronary Computed Tomography Angiography by 16-Slice Multi-Detector Computed Tomography in Japanese Patients with Suspected Ischemic Cardiac Disease. / Hirano, Masaharu; Yamashina, Akira; Hara, Kazuhiro et al.
In: Drugs in R and D, Vol. 14, No. 3, 01.09.2014, p. 185-194.

Research output: Contribution to journal › Article › peer-review

Hirano, M, Yamashina, A, Hara, K, Ikari, Y, Jinzaki, M, Iino, M, Yamaguchi, T, Tanimoto, M & Kuribayashi, S 2014, 'A Multicenter, Open-Label Study of an Intravenous Short-Acting β₁-Adrenergic Receptor Antagonist Landiolol Hydrochloride for Coronary Computed Tomography Angiography by 16-Slice Multi-Detector Computed Tomography in Japanese Patients with Suspected Ischemic Cardiac Disease', Drugs in R and D, vol. 14, no. 3, pp. 185-194. https://doi.org/10.1007/s40268-014-0056-6

Hirano M, Yamashina A, Hara K, Ikari Y, Jinzaki M, Iino M et al. A Multicenter, Open-Label Study of an Intravenous Short-Acting β₁-Adrenergic Receptor Antagonist Landiolol Hydrochloride for Coronary Computed Tomography Angiography by 16-Slice Multi-Detector Computed Tomography in Japanese Patients with Suspected Ischemic Cardiac Disease. Drugs in R and D. 2014 Sept 1;14(3):185-194. doi: 10.1007/s40268-014-0056-6

Hirano, Masaharu ; Yamashina, Akira ; Hara, Kazuhiro et al. / A Multicenter, Open-Label Study of an Intravenous Short-Acting β₁-Adrenergic Receptor Antagonist Landiolol Hydrochloride for Coronary Computed Tomography Angiography by 16-Slice Multi-Detector Computed Tomography in Japanese Patients with Suspected Ischemic Cardiac Disease. In: Drugs in R and D. 2014 ; Vol. 14, No. 3. pp. 185-194.

@article{950691c1062247a6aa397b070348daec,

title = "A Multicenter, Open-Label Study of an Intravenous Short-Acting β1-Adrenergic Receptor Antagonist Landiolol Hydrochloride for Coronary Computed Tomography Angiography by 16-Slice Multi-Detector Computed Tomography in Japanese Patients with Suspected Ischemic Cardiac Disease",

abstract = "Conclusions: Landiolol hydrochloride was confirmed to reduce heart rate significantly and rapidly after intravenous injection and this suggests that the study drug is a safe and useful agent for improving the image quality of CCTA by 16-slice MDCT.Background: During coronary computed tomography (CT) angiography (CCTA), β-blockers (β-adrenergic receptor antagonists) have commonly been used to lower heart rate and improve image quality.Results: The diagnosable proportions for the reconstruction images at mid-diastole were 56.0 %. The diagnosable proportions for the optimal reconstruction images were 65.4 %. The mean heart rate-lowering effect was observed soon after administration of landiolol hydrochloride; the peak of the effect was reached in 3–5 min, and the effect wore off in 30 min after completion of administration. The mean heart rate-lowering proportion at that time was −14.46 ± 8.4 %.Objectives: The aim of this study was to investigate the image quality-improving effect as well as the heart rate-lowering effect of landiolol hydrochloride (an intravenous short-acting β1-adrenergic receptor antagonist) in CCTA by 16-slice multi-detector CT (MDCT).Methods: A total of 39 subjects suspected of having ischemic cardiac disease and requiring CCTA received 0.125 mg/kg of landiolol hydrochloride to study the efficacy and safety of landiolol hydrochloride in a multicenter open-label clinical study. The endpoint was the diagnosable proportion (proportion of subjects whose coronary stenosis was diagnosable).",

author = "Masaharu Hirano and Akira Yamashina and Kazuhiro Hara and Yuji Ikari and Masahiro Jinzaki and Misako Iino and Takuhiro Yamaguchi and Mitsunobu Tanimoto and Sachio Kuribayashi",

note = "Funding Information: Acknowledgments This study was supported by a grant from Ono Pharmaceutical Co., Ltd., Osaka, Japan, the manufacturer of landiolol hydrochloride. Masaharu Hirano, Kazuhiro Hara, Yuji Ikari, Masa-hiro Jinzaki, Misako Iino, Takuhiro Yamaguchi, and Sachio Kuri-bayashi received consulting fees from Ono Pharmaceutical Co., Ltd. We gratefully acknowledge the contributions of the members of the Landiolol Hydrochloride Study Group (listed in the Appendix) to this study, as well as of Dr. Hiroshi Higashino, Dr. Masahiro Higashi, and Dr. Teruhito Kido (Central Coronary Visualization Judgment Committee). Publisher Copyright: {\textcopyright} 2014, The Author(s).",

year = "2014",

month = sep,

day = "1",

doi = "10.1007/s40268-014-0056-6",

language = "English",

volume = "14",

pages = "185--194",

journal = "Drugs in R and D",

issn = "1174-5886",

publisher = "Adis International Ltd",

number = "3",

}

TY - JOUR

T1 - A Multicenter, Open-Label Study of an Intravenous Short-Acting β1-Adrenergic Receptor Antagonist Landiolol Hydrochloride for Coronary Computed Tomography Angiography by 16-Slice Multi-Detector Computed Tomography in Japanese Patients with Suspected Ischemic Cardiac Disease

AU - Hirano, Masaharu

AU - Yamashina, Akira

AU - Hara, Kazuhiro

AU - Ikari, Yuji

AU - Jinzaki, Masahiro

AU - Iino, Misako

AU - Yamaguchi, Takuhiro

AU - Tanimoto, Mitsunobu

AU - Kuribayashi, Sachio

N1 - Funding Information: Acknowledgments This study was supported by a grant from Ono Pharmaceutical Co., Ltd., Osaka, Japan, the manufacturer of landiolol hydrochloride. Masaharu Hirano, Kazuhiro Hara, Yuji Ikari, Masa-hiro Jinzaki, Misako Iino, Takuhiro Yamaguchi, and Sachio Kuri-bayashi received consulting fees from Ono Pharmaceutical Co., Ltd. We gratefully acknowledge the contributions of the members of the Landiolol Hydrochloride Study Group (listed in the Appendix) to this study, as well as of Dr. Hiroshi Higashino, Dr. Masahiro Higashi, and Dr. Teruhito Kido (Central Coronary Visualization Judgment Committee). Publisher Copyright: © 2014, The Author(s).

PY - 2014/9/1

Y1 - 2014/9/1

N2 - Conclusions: Landiolol hydrochloride was confirmed to reduce heart rate significantly and rapidly after intravenous injection and this suggests that the study drug is a safe and useful agent for improving the image quality of CCTA by 16-slice MDCT.Background: During coronary computed tomography (CT) angiography (CCTA), β-blockers (β-adrenergic receptor antagonists) have commonly been used to lower heart rate and improve image quality.Results: The diagnosable proportions for the reconstruction images at mid-diastole were 56.0 %. The diagnosable proportions for the optimal reconstruction images were 65.4 %. The mean heart rate-lowering effect was observed soon after administration of landiolol hydrochloride; the peak of the effect was reached in 3–5 min, and the effect wore off in 30 min after completion of administration. The mean heart rate-lowering proportion at that time was −14.46 ± 8.4 %.Objectives: The aim of this study was to investigate the image quality-improving effect as well as the heart rate-lowering effect of landiolol hydrochloride (an intravenous short-acting β1-adrenergic receptor antagonist) in CCTA by 16-slice multi-detector CT (MDCT).Methods: A total of 39 subjects suspected of having ischemic cardiac disease and requiring CCTA received 0.125 mg/kg of landiolol hydrochloride to study the efficacy and safety of landiolol hydrochloride in a multicenter open-label clinical study. The endpoint was the diagnosable proportion (proportion of subjects whose coronary stenosis was diagnosable).

AB - Conclusions: Landiolol hydrochloride was confirmed to reduce heart rate significantly and rapidly after intravenous injection and this suggests that the study drug is a safe and useful agent for improving the image quality of CCTA by 16-slice MDCT.Background: During coronary computed tomography (CT) angiography (CCTA), β-blockers (β-adrenergic receptor antagonists) have commonly been used to lower heart rate and improve image quality.Results: The diagnosable proportions for the reconstruction images at mid-diastole were 56.0 %. The diagnosable proportions for the optimal reconstruction images were 65.4 %. The mean heart rate-lowering effect was observed soon after administration of landiolol hydrochloride; the peak of the effect was reached in 3–5 min, and the effect wore off in 30 min after completion of administration. The mean heart rate-lowering proportion at that time was −14.46 ± 8.4 %.Objectives: The aim of this study was to investigate the image quality-improving effect as well as the heart rate-lowering effect of landiolol hydrochloride (an intravenous short-acting β1-adrenergic receptor antagonist) in CCTA by 16-slice multi-detector CT (MDCT).Methods: A total of 39 subjects suspected of having ischemic cardiac disease and requiring CCTA received 0.125 mg/kg of landiolol hydrochloride to study the efficacy and safety of landiolol hydrochloride in a multicenter open-label clinical study. The endpoint was the diagnosable proportion (proportion of subjects whose coronary stenosis was diagnosable).

UR - http://www.scopus.com/inward/record.url?scp=84930006115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930006115&partnerID=8YFLogxK

U2 - 10.1007/s40268-014-0056-6

DO - 10.1007/s40268-014-0056-6

M3 - Article

C2 - 25091378

AN - SCOPUS:84930006115

SN - 1174-5886

VL - 14

SP - 185

EP - 194

JO - Drugs in R and D

JF - Drugs in R and D

IS - 3

ER -